Using ddPCR and a PNA Clamp TaqMan assay, we have detected the presence of pretreatment EGFR-Thr790Met mutation in 26.5% of stage IV NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.